🇺🇸

US SEC Filing Intelligence

· daily

High-Value Federal Grants ($5M+) — March 15, 2026

Four high-value federal contracts totaling $1.64B signal robust near- to long-term revenue for contractors in DHS border/immigration infrastructure (62% of value) and construction services, with full obligations but minimal outlays ($107M total) indicating deferred cash flows through 2026-2029. Firm-fixed-price structures dominate, exposing winners to cost risks amid inflation/labor pressures. Investors should prioritize DHS-exposed construction firms for revenue visibility, monitoring outlay ramps and follow-on awards.

4 total filings
· daily

General Federal Contracts — March 15, 2026

Four federal contracts totaling $1.64B underscore prioritized U.S. government spending on border security infrastructure (62% via DHS at $1.03B), diplomatic construction, and FAA communications sustainment. All awards are fully obligated firm-fixed-price deals with minimal outlays ($107M total), offering revenue visibility through 2026-2029 but exposing winners to execution risks. Construction dominates (3/4 contracts, $1.27B), signaling multi-year tailwinds for sector incumbents amid low current cash realization.

4 total filings
· daily

Global High-Priority Regulatory Events — March 15, 2026

Across these two high-priority market event filings, themes center on operational stability amid rumors in the metals sector and upcoming earnings catalysts in IT services, both from major Indian firms with US exposure via ADRs. Hindalco's positive rumor verification highlights minimal disruption (<0.1% impact) from gas supplier force majeure, underscoring resilience in commodities amid geopolitical noise like Iran war reports. Infosys announces a high-materiality (9/10) board meeting for Q4/FY2026 results and potential dividend, signaling routine but critical capital allocation decisions under SEBI compliance. No direct period-over-period financial trends are reported in these event-driven filings, but forward-looking catalysts dominate, with Infosys' trading window closure (March 16-April 27, 2026) implying material non-public info. Portfolio-level patterns show low-risk clarification for Hindalco (materiality 3/10) versus high-impact earnings for Infosys, suggesting relative outperformance potential in IT over metals short-term. Market implications include reduced uncertainty for Hindalco and pre-earnings positioning for Infosys, with both reinforcing SEBI regulatory transparency.

2 high priority 2 total filings
· daily

DHS Homeland Security Contracts — March 14, 2026

DHS stream delivers $241M in contracts with performance into 2026-27, dominated by Coast Guard engineering/UAS awards to Boeing/Insitu ($96M) and Lockheed Martin ($65M combined), signaling sustained homeland security modernization spending. Three bullish signals highlight revenue visibility for defense primes and small IT firms amid zero outlays indicating front-loaded obligations. Investors should prioritize Boeing and Lockheed for near-term backlog growth, monitoring execution as periods extend through mid-2026.

4 total filings
· daily

VA Healthcare & Services Contracts — March 14, 2026

VA awarded $1.65B in healthcare and services contracts over this period, with 80% bullish signals concentrated in health insurance ($820M to TriWest) and IT services ($377M obligated, up to $795M with options). High outlays in evaluation ($364M/381M) and IT ($233M/377M) signal immediate revenue for veteran-aligned providers, while options offer $419M+ upside. Firm-fixed pricing dominates, flagging cost overrun risks amid varying execution timelines.

5 total filings
· daily

HHS & Healthcare Contracts Intelligence — March 14, 2026

BARDA's $980M in biotech R&D contracts signal robust, long-term U.S. biodefense funding through 2032, with full obligations (base + options) exceeding $1.7B potential. MAPP Biopharmaceutical's bullish $185M award (47% outlayed, $907M upside) highlights small-cap viral therapeutics momentum, contrasting neutral nonprofit stability at Advanced Technology International ($14M of $795M outlayed). Investors should prioritize equity exposure in small biopharma over nonprofits amid early-stage execution variances.

2 total filings
· daily

Federal Construction & Infrastructure Contracts — March 14, 2026

A single $75.8M VA contract to SDVOSB Richard Group LLC for EHRM infrastructure upgrades at Hines, IL, represents full federal obligation in hospital construction with performance through 2027-03-09, signaling targeted veteran healthcare spending. Neutral overall impact limits broader sector alpha due to small business set-aside, but provides revenue visibility amid zero outlays to date. Execution risks from firm-fixed-price structure warrant monitoring for cost overruns in this concentrated NAICS 236220 award.

1 total filings
· daily

Federal Professional Services Contracts — March 14, 2026

Lockheed Martin dominates with two sole-source Time & Materials contracts totaling $64.97M from US Coast Guard for Sea Commander engineering/C4ISR ($42.13M, bullish) and sustainment ($22.84M, neutral), locking in revenue through Apr 2026 despite $0 outlays to date. This concentration highlights entrenched positioning in DHS professional engineering services but flags execution delays after 3+ years. Investors gain visibility into steady defense services backlog amid sole-source favoritism.

2 total filings
· daily

Federal IT & Cybersecurity Contracts — March 14, 2026

Five bullish contracts totaling $943M in obligations signal robust federal demand for IT systems design (NAICS 541512), with base+options ceiling exceeding $1.9B, providing multi-year revenue visibility through 2029. VA dominates with ~40% of value across two awards, underscoring priority on veteran-focused IT/DevSecOps. Small/disadvantaged businesses captured 3/5 awards via set-asides, highlighting competitive edges in federal procurement amid full/open competition wins by larger players.

5 total filings
· daily

New Federal Contractors — March 14, 2026

This period's $4.99B in new federal contracts is dominated by VA and HHS awards totaling ~$2.7B (54%), signaling robust demand for healthcare services, medical evaluations, and biotech R&D amid long-term commitments to 2032. Bullish signals prevail (12/15) for public firms like L3Harris ($814M NASA space tech) and Lockheed Martin ($65M DHS engineering), with private players capturing bulk via full competition wins. Option-heavy structures (~$3B+ potential upside across contracts) offer multi-year revenue expansion, though firm-fixed-price prevalence flags execution risks.

15 total filings
· daily

Significant Contract Modifications ($10M+) — March 14, 2026

This $4.99B batch of significant contract modifications signals robust federal spending on healthcare/IT services, particularly VA/HHS ($3.0B+ across 8 awards), providing multi-year revenue visibility to winners like TriWest ($820M health insurance) and L3Harris ($814M space tech). Bullish for large primes in health R&D, veteran services, and defense IT, with 12/15 signals positive, though firm-fixed-price structures and long durations (many to 2029+) flag execution risks. Neutral on nonprofits/small biz due to limited equity upside, but options/upside potential totals $2B+ across deals.

15 total filings
· daily

Contract Deobligations Alert — March 14, 2026

This week's $4.99B in federal contract obligations signal robust demand for healthcare services (VA/HHS ~$2.8B or 56%), space/defense, and IT, with 12 bullish signals dominated by long-term awards to TriWest, L3Harris, and BL Harbert exceeding $800M each. Institutional investors should prioritize large-cap exposure (L3Harris, Lockheed) and VA-aligned veteran-owned firms for revenue visibility through 2029+, while monitoring firm fixed price risks and low outlays ($1.9B or 38% disbursed). Neutral signals on nonprofits/small businesses limit equity upside but highlight sector funding stability.

15 total filings
· daily

Contract Option Exercises — March 14, 2026

This period's $4.99B in contract option exercises signals strong federal commitment to healthcare (VA/HHS ~$2.8B or 56%), IT services (~$1.1B or 22%), and defense/space systems, with 12/15 bullish awards dominated by full/open competition wins. Largest awards (> $400M) to TriWest, L3Harris, BL Harbert highlight revenue visibility through 2026-2032, though short-duration outliers like TriWest's $820M 1-month deal raise execution questions. Investors should prioritize VA/IT exposed large caps (L3Harris, Lockheed) and monitor option exercises for ~$2B+ upside across contracts.

15 total filings
· daily

All HHS Contracts — March 14, 2026

HHS awarded $1.04B in obligations across three contracts, with 94% ($980M) concentrated in BARDA biotech R&D for pandemic threats, signaling sustained federal prioritization. Two bullish small business awards to MAPP Biopharma ($185M obligation, $907M ceiling) and ThirdPacket ($64M obligation, $128M ceiling) highlight equity growth potential via options, contrasting neutral nonprofit funding to Advanced Technology International ($795M). Long durations to 2029-2032 underscore stable revenue but execution risks from low outlays (avg. 20%).

3 total filings
· daily

Mega Contracts Monitor ($100M+) — March 14, 2026

Nine mega contracts totaling $4.6B awarded or active, with 8 bullish signals dominated by VA ($1.58B across 4 contracts) and HHS/BARDA ($980M across 2), signaling robust federal healthcare and biotech spending through 2029+. Long-term performance periods (avg. 5+ years) provide revenue visibility, though firm fixed price structures (6/9) heighten execution risks amid low average outlays ($13-94% realized). Institutional investors should prioritize L3Harris (public, $814M NASA) and VA/IT specialists for multi-year upside via options exceeding $2B potential.

9 total filings
· daily

High-Value Federal Grants ($5M+) — March 14, 2026

This period's $4.99B in high-value federal contracts is dominated by healthcare/VA awards (e.g., $819M TriWest, $381M Veterans Evaluation), signaling robust demand for medical and IT services amid long-term commitments to 2029+. Defense primes like L3Harris ($814M NASA) and Lockheed Martin ($65M DHS combined) benefit from stable revenue in space and C4ISR, with significant option upside across portfolio (~$2.5B+ potential). Investors should prioritize public equities in aerospace/defense while monitoring execution risks from firm-fixed-price structures and $0 outlays on several large awards.

15 total filings
· daily

General Federal Contracts — March 14, 2026

This $4.99B batch of federal contracts signals robust U.S. government commitment to health services, IT, biotech R&D, and space/defense, with 12 bullish awards dominated by VA ($1.65B across 5 contracts) and HHS ($1.04B across 3). Top winners TriWest ($820M VA health insurance), L3Harris ($814M NASA space tech), and BL Harbert ($814M State construction) offer multi-year revenue visibility to 2029+. Investors should prioritize large-cap exposure (L3Harris, Lockheed) and monitor option exercises adding $2B+ potential upside across deals.

15 total filings
· daily

All NASA Contracts — March 14, 2026

NASA's $814M obligation to L3Harris for CRIS instrument engineering and services through 2029 provides high-confidence, long-term revenue stability in space vehicle components (PSC 1820). With $216M already outlayed and $833M base+options potential, this underscores NASA commitment amid execution risks from 19-year duration and $168M subawards. Institutional investors gain actionable bullish signal for L3Harris, offset by monitoring subcontractor performance and tech obsolescence.

1 total filings
· daily

Global High-Priority Regulatory Events — March 14, 2026

The 17 filings reveal a surge in high-priority distress events among Indian listed companies, dominated by insolvency proceedings (10/17), with 70% showing positive progress via settlements, unanimous approvals, and scheme sanctions, signaling potential turnarounds amid CIRP protections. Negative outliers include Reliance Communications' subsidiary fraud classification on ₹375 Cr pre-CIRP loans (₹125 Cr SBI), Tijaria Polypipes' new Bank of India insolvency petition, and Olympic Cards' ₹0.15 Cr loan default on ₹15.5 Cr facility. No aggregate period-over-period financial trends available, but specific metrics highlight distress like Olympic's ₹9.28 Cr bank borrowings and 100% creditor approvals in restructurings (e.g., Share India 99.8% equity votes). Open offers (Lykis, Satani Bearings) and minor regulatory actions (Manappuram ₹2.7L penalty) add neutral-to-positive M&A/takeover themes. Three medium-risk encumbrances (Anand Rathi Wealth, India Finsec, unknown) warrant monitoring. Portfolio implications: Bullish resolution momentum for alpha in distressed assets, bearish fraud/default risks for avoidance; key catalysts cluster March-April 2026.

17 high priority 17 total filings